Investigating Patient-Specific Absorbed Dose Assessment for Copper-64 PET/CT
-
Ali Abdulhasan Kadhim
,
Peyman Sheikhzadeh
,
Mehrshad Abbasi
,
Saeed Afshar
,
Nasim Vahidfar
,
Shirin Asidkar
,
Mehrnoosh Karimipourfard
,
Zahra Valibeiglou
,
Mohammad Reza Ay
Abstract
Purpose: There is a growing interest in the clinical application of new PET radiopharmaceuticals. This study focuses on using 64Cu-DOTA-Trastuzumab for Positron Emission Tomography–Computed Tomography (PET/CT) imaging in gastric cancer patients. It aims to enhance the understanding of its bio-kinetic distribution and absorbed dose for safe and practical application in nuclear medicine.
Materials and Methods: The study was conducted at the Agricultural, Medical, and Industrial Research School (AMIRS), where 64Cu was produced and purified. The radiopharmaceutical 64Cu-DOTA-Trastuzumab was prepared, and three patients with confirmed Human Epidermal growth factor Receptor 2 (HER2)-positive gastric cancer underwent PET/CT scans at 1, 12 and 48 hours post-injection. Images were gained using a Discovery IQ PET/CT system and analyzed for an SUV. Bio-distribution was modeled using a two-exponential function, and absorbed doses were calculated using IDAC-Dose 2.1 software. CT doses were also evaluated.
Results: The study found that post-injection imaging at 12 hours or more provided superior image quality. The liver exhibited the highest cumulative activity, followed by the spleen and other organs. The effective dose estimates for 64Cu-DOTA-Trastuzumab were within acceptable limits. CT dose calculations revealed that sensitive organs received higher doses.
Conclusion: This study successfully assessed the bio-kinetic distribution and absorbed dose of 64Cu-DOTA-Trastuzumab in gastric cancer patients, demonstrating its safety and potential for clinical use. The optimal timing for PET/CT imaging and dosimetry data can inform clinical decision-making. Further research is warranted to explore the therapeutic potential of 64Cu-DOTA-Trastuzumab and to establish clinical guidelines for its use.
1- Y. Zhou et al., "(64)Cu-based Radiopharmaceuticals in Molecular Imaging." (in eng), Technol Cancer Res Treat, Vol. 18p. 1533033819830758, Jan 1 (2019).
2- M. Shokeen and C. J. Anderson, "Molecular imaging of cancer with copper-64 radiopharmaceuticals and positron emission tomography (PET)." (in eng), Acc Chem Res, Vol. 42 (No. 7), pp. 832-41, Jul 21 (2009).
3- J. P. Holland, R. Ferdani, C. J. Anderson, and J. S. Lewis, "Copper-64 Radiopharmaceuticals for Oncologic Imaging." (in eng), PET Clin, Vol. 4 (No. 1), pp. 49-67, Jan (2009).
4- B. Grubmüller et al., "(64)Cu-PSMA-617 PET/CT Imaging of Prostate Adenocarcinoma: First In-Human Studies." (in eng), Cancer Biother Radiopharm, Vol. 31 (No. 8), pp. 277-86, Oct (2016).
5- C. J. Anderson and R. Ferdani, "Copper-64 radiopharmaceuticals for PET imaging of cancer: advances in preclinical and clinical research." (in eng), Cancer Biother Radiopharm, Vol. 24 (No. 4), pp. 379-93, Aug (2009).
6- Lei Jiang et al., "Pilot Study of 64Cu(I) for PET Imaging of Melanoma." Scientific Reports, Vol. 7 (No. 1), p. 2574, 2017/05/31 (2017).
7- B. Gutfilen, S. A. Souza, and G. Valentini, "Copper-64: a real theranostic agent." (in eng), Drug Des Devel Ther, Vol. 12pp. 3235-45, (2018).
8- C. Bailly et al., "Comparison of Immuno-PET of CD138 and PET imaging with (64)CuCl(2) and (18)F-FDG in a preclinical syngeneic model of multiple myeloma." (in eng), Oncotarget, Vol. 9 (No. 10), pp. 9061-72, Feb 6 (2018).
9- M. N. Amiot et al., "Standardization of 64Cu using an improved decay scheme." Nuclear Instruments and Methods in Physics Research Section A: Accelerators, Spectrometers, Detectors and Associated Equipment, Vol. 684pp. 97-104, 2012/08/21/ (2012).
10- A. Monsef, P. Sheikhzadeh, J. R. Steiner, F. Sadeghi, M. Yazdani, and P. Ghafarian, "Optimizing scan time and bayesian penalized likelihood reconstruction algorithm in copper-64 PET/CT imaging: a phantom study." (in eng), Biomed Phys Eng Express, Vol. 10 (No. 4), May 14 (2024).
11- "In This Issue." Molecular Therapy, Vol. 25 (No. 12), (2017).
12- Vahidfar Nasim et al., "Recent Advances of Copper-64 Based Radiopharmaceuticals in Nuclear Medicine." in Advances in Dosimetry and New Trends in Radiopharmaceuticals, Osibote Otolorin Adelaja and Eppard Elisabeth, Eds. Rijeka: IntechOpen, (2024), p. Ch. 5.
13- S. Heidari, M. Sadeghi, M. Akhlaghi, D. Beiki, and S. I. Yazdi, "Internal dosimetry of (64)Cu-DOX-loaded microcapsules by Monte Carlo method." (in eng), Appl Radiat Isot, Vol. 196p. 110788, Jun (2023).
14- Tengzhi Liu, Morten Karlsen, Anna Karlberg, and Kathrine Redalen, "Hypoxia imaging and theranostic potential of [64Cu][Cu(ATSM)] and ionic Cu(II) salts: a review of current evidence and discussion of the retention mechanisms." EJNMMI Research, Vol. 10p. 33, 04/09 (2020).
15- Francesco Fiz et al., "Diagnostic and Dosimetry Features of [64Cu]CuCl2 in High-Grade Paediatric Infiltrative Gliomas." Molecular Imaging and Biology, Vol. 2508/30 (2022).
16- M. A. Avila-Rodriguez et al., "Biodistribution and radiation dosimetry of [(64)Cu]copper dichloride: first-in-human study in healthy volunteers." (in eng), EJNMMI Res, Vol. 7 (No. 1), p. 98, Dec 12 (2017).
17- J. E. Mortimer et al., "Use of (64)Cu-DOTA-Trastuzumab PET to Predict Response and Outcome of Patients Receiving Trastuzumab Emtansine for Metastatic Breast Cancer: A Pilot Study." (in eng), J Nucl Med, Vol. 63 (No. 8), pp. 1145-48, Aug (2022).
18- Copper-64 Radiopharmaceuticals: Production, Quality Control and Clinical Applications. Vienna: INTERNATIONAL ATOMIC ENERGY AGENCY, (2022).
19- C Nioche, F Orlhac, S Boughdad, S Reuzé, J Goya-Outi, C Robert, C Pellot-Barakat, M Soussan, F Frouin, and I Buvat. "LIFEx: a freeware for radiomic feature calculation in multimodality imaging to accelerate advances in the characterization of tumor heterogeneity." Cancer Research; 78(16):4786-4789, (2018).
20- Al-Fatlawi, Murtadha, Farideh Pak, Saeed Farzanefar, Yalda Salehi, Abbas Monsef, and Peyman Sheikhzadeh. "Optimization of the Acquisition Time and Injected Dose of 18F-Fluorodeoxyglucose Based on Patient Specifications for High-Sensitive Positron Emission Tomography/Computed Tomography Scanner." World Journal of Nuclear Medicine 22, no. 03: 196-202, (2023)."
21- Sara Neira et al., "Quantification of internal dosimetry in PET patients: individualized Monte Carlo vs generic phantom‐based calculations." Medical Physics, Vol. 47 (No. 9), pp. 4574-88, (2020).
22- M. Karimipourfard, S. Sina, and M. S. Alavi, "Toward three-dimensional patient-specific internal dosimetry using GATE Monte Carlo technique." Radiation Physics and Chemistry, Vol. 195p. 110046, 2022/06/01/ (2022).
23- Cassandra Métivier et al., "Preclinical Evaluation of a 64Cu-Based Theranostic Approach in a Murine Model of Multiple Myeloma." Pharmaceutics. Vol. 15 (No. 7). DOI: 10.3390/pharmaceutics15071817
24- S. Soongsathitanon, P. Masa-Ah, and Malulee Tuntawiroon, "A new Standard Uptake Values (SUV) calculation based on pixel intensity values." Vol. 6pp. 26-33, 01/01 (2012).
25- M. Andersson, L. Johansson, K. Eckerman, and S. Mattsson, "IDAC-Dose 2.1, an internal dosimetry program for diagnostic nuclear medicine based on the ICRP adult reference voxel phantoms." (in eng), EJNMMI Res, Vol. 7 (No. 1), p. 88, Nov 3 (2017).
26- Matthew Large, Alessandra Malaroda, Marco Petasecca, Anatoly Rosenfeld, and S. Guatelli, Modelling ICRP110 Adult Reference Voxel Phantoms for dosimetric applications: Development of a new Geant4 Advanced Example. (2020).
27- Samira Kamrani, Nima Kasraie, Fatemeh Jahangiri, Davood Khezrloo, and Peyman Sheikhzadeh, "Organ doses, effective dose, and cancer risk estimation from head and neck CT scans." Radiation Physics and Chemistry, Vol. 212p. 111163, 07/01 (2023).
28- C. Anam, F. Haryanto, R. Widita, I. Arif, G. Dougherty, and D. McLean, "Volume computed tomography dose index (CTDIvol) and size-specific dose estimate (SSDE) for tube current modulation (TCM) in CT scanning." Int-J-Radiat-Res, Vol. 16 (No. 3), pp. 289-97, (2018).
29- I. Lange, B. Alikhani, F. Wacker, and H. J. Raatschen, "Intraindividual variation of dose parameters in oncologic CT imaging." (in eng), PLoS One, Vol. 16 (No. 4), p. e0250490, (2021).
30- Rubel Chakravarty, Hao Hong, and Weibo Cai, "Positron Emission Tomography Image-Guided Drug Delivery: Current Status and Future Perspectives." Molecular Pharmaceutics, Vol. 11 (No. 11), pp. 3777-97, 2014/11/03 (2014).
31- Sally Pimlott and Andrew Sutherland, "Molecular tracers for the PET and SPECT imaging of disease." Chemical Society reviews, Vol. 40pp. 149-62, 04/19 (2011).
32- Samira Heidari, Mahdi Sadeghi, Mehdi Akhlaghi, Davood Beiki, and Saeideh Yazdi, "Internal dosimetry of 64Cu-DOX-loaded microcapsules by Monte Carlo method." Applied Radiation and Isotopes, Vol. 196p. 110788, 03/01 (2023).
33- A. W. Wong et al., "A comparison of image contrast with (64)Cu-labeled long circulating liposomes and (18)F-FDG in a murine model of mammary carcinoma." (in eng), Am J Nucl Med Mol Imaging, Vol. 3 (No. 1), pp. 32-43, (2013).
34- P. S. Iyer, "Current radiation protection standards: ICRP-60." Indian Journal of Radiology and Imaging, Vol. 5 (No. 2), pp. 81-83, (1995).
35- Karimipourfard, M., S. Sina, and M. S. Alavi. "Toward three-dimensional patient-specific internal dosimetry using GATE Monte Carlo technique." Radiation Physics and Chemistry 195, 110046, (2022).
36- Jean-Claude Nenot, Jean Brenot, Dominique Laurier, Alain Rannou, and Dominique Thierry, "ICRP Publication 103 The 2007 Recommendations of the International Commission on Radiological Protection." France, 978-2-7430-1120-8, (2009), [Online]. Available: http://inis.iaea.org/search/search.aspx?orig_q=RN:49042116.
37- K. Tamura et al., "64Cu-DOTA-trastuzumab PET imaging in patients with HER2-positive breast cancer." (in eng), J Nucl Med, Vol. 54 (No. 11), pp. 1869-75, Nov (2013).
2- M. Shokeen and C. J. Anderson, "Molecular imaging of cancer with copper-64 radiopharmaceuticals and positron emission tomography (PET)." (in eng), Acc Chem Res, Vol. 42 (No. 7), pp. 832-41, Jul 21 (2009).
3- J. P. Holland, R. Ferdani, C. J. Anderson, and J. S. Lewis, "Copper-64 Radiopharmaceuticals for Oncologic Imaging." (in eng), PET Clin, Vol. 4 (No. 1), pp. 49-67, Jan (2009).
4- B. Grubmüller et al., "(64)Cu-PSMA-617 PET/CT Imaging of Prostate Adenocarcinoma: First In-Human Studies." (in eng), Cancer Biother Radiopharm, Vol. 31 (No. 8), pp. 277-86, Oct (2016).
5- C. J. Anderson and R. Ferdani, "Copper-64 radiopharmaceuticals for PET imaging of cancer: advances in preclinical and clinical research." (in eng), Cancer Biother Radiopharm, Vol. 24 (No. 4), pp. 379-93, Aug (2009).
6- Lei Jiang et al., "Pilot Study of 64Cu(I) for PET Imaging of Melanoma." Scientific Reports, Vol. 7 (No. 1), p. 2574, 2017/05/31 (2017).
7- B. Gutfilen, S. A. Souza, and G. Valentini, "Copper-64: a real theranostic agent." (in eng), Drug Des Devel Ther, Vol. 12pp. 3235-45, (2018).
8- C. Bailly et al., "Comparison of Immuno-PET of CD138 and PET imaging with (64)CuCl(2) and (18)F-FDG in a preclinical syngeneic model of multiple myeloma." (in eng), Oncotarget, Vol. 9 (No. 10), pp. 9061-72, Feb 6 (2018).
9- M. N. Amiot et al., "Standardization of 64Cu using an improved decay scheme." Nuclear Instruments and Methods in Physics Research Section A: Accelerators, Spectrometers, Detectors and Associated Equipment, Vol. 684pp. 97-104, 2012/08/21/ (2012).
10- A. Monsef, P. Sheikhzadeh, J. R. Steiner, F. Sadeghi, M. Yazdani, and P. Ghafarian, "Optimizing scan time and bayesian penalized likelihood reconstruction algorithm in copper-64 PET/CT imaging: a phantom study." (in eng), Biomed Phys Eng Express, Vol. 10 (No. 4), May 14 (2024).
11- "In This Issue." Molecular Therapy, Vol. 25 (No. 12), (2017).
12- Vahidfar Nasim et al., "Recent Advances of Copper-64 Based Radiopharmaceuticals in Nuclear Medicine." in Advances in Dosimetry and New Trends in Radiopharmaceuticals, Osibote Otolorin Adelaja and Eppard Elisabeth, Eds. Rijeka: IntechOpen, (2024), p. Ch. 5.
13- S. Heidari, M. Sadeghi, M. Akhlaghi, D. Beiki, and S. I. Yazdi, "Internal dosimetry of (64)Cu-DOX-loaded microcapsules by Monte Carlo method." (in eng), Appl Radiat Isot, Vol. 196p. 110788, Jun (2023).
14- Tengzhi Liu, Morten Karlsen, Anna Karlberg, and Kathrine Redalen, "Hypoxia imaging and theranostic potential of [64Cu][Cu(ATSM)] and ionic Cu(II) salts: a review of current evidence and discussion of the retention mechanisms." EJNMMI Research, Vol. 10p. 33, 04/09 (2020).
15- Francesco Fiz et al., "Diagnostic and Dosimetry Features of [64Cu]CuCl2 in High-Grade Paediatric Infiltrative Gliomas." Molecular Imaging and Biology, Vol. 2508/30 (2022).
16- M. A. Avila-Rodriguez et al., "Biodistribution and radiation dosimetry of [(64)Cu]copper dichloride: first-in-human study in healthy volunteers." (in eng), EJNMMI Res, Vol. 7 (No. 1), p. 98, Dec 12 (2017).
17- J. E. Mortimer et al., "Use of (64)Cu-DOTA-Trastuzumab PET to Predict Response and Outcome of Patients Receiving Trastuzumab Emtansine for Metastatic Breast Cancer: A Pilot Study." (in eng), J Nucl Med, Vol. 63 (No. 8), pp. 1145-48, Aug (2022).
18- Copper-64 Radiopharmaceuticals: Production, Quality Control and Clinical Applications. Vienna: INTERNATIONAL ATOMIC ENERGY AGENCY, (2022).
19- C Nioche, F Orlhac, S Boughdad, S Reuzé, J Goya-Outi, C Robert, C Pellot-Barakat, M Soussan, F Frouin, and I Buvat. "LIFEx: a freeware for radiomic feature calculation in multimodality imaging to accelerate advances in the characterization of tumor heterogeneity." Cancer Research; 78(16):4786-4789, (2018).
20- Al-Fatlawi, Murtadha, Farideh Pak, Saeed Farzanefar, Yalda Salehi, Abbas Monsef, and Peyman Sheikhzadeh. "Optimization of the Acquisition Time and Injected Dose of 18F-Fluorodeoxyglucose Based on Patient Specifications for High-Sensitive Positron Emission Tomography/Computed Tomography Scanner." World Journal of Nuclear Medicine 22, no. 03: 196-202, (2023)."
21- Sara Neira et al., "Quantification of internal dosimetry in PET patients: individualized Monte Carlo vs generic phantom‐based calculations." Medical Physics, Vol. 47 (No. 9), pp. 4574-88, (2020).
22- M. Karimipourfard, S. Sina, and M. S. Alavi, "Toward three-dimensional patient-specific internal dosimetry using GATE Monte Carlo technique." Radiation Physics and Chemistry, Vol. 195p. 110046, 2022/06/01/ (2022).
23- Cassandra Métivier et al., "Preclinical Evaluation of a 64Cu-Based Theranostic Approach in a Murine Model of Multiple Myeloma." Pharmaceutics. Vol. 15 (No. 7). DOI: 10.3390/pharmaceutics15071817
24- S. Soongsathitanon, P. Masa-Ah, and Malulee Tuntawiroon, "A new Standard Uptake Values (SUV) calculation based on pixel intensity values." Vol. 6pp. 26-33, 01/01 (2012).
25- M. Andersson, L. Johansson, K. Eckerman, and S. Mattsson, "IDAC-Dose 2.1, an internal dosimetry program for diagnostic nuclear medicine based on the ICRP adult reference voxel phantoms." (in eng), EJNMMI Res, Vol. 7 (No. 1), p. 88, Nov 3 (2017).
26- Matthew Large, Alessandra Malaroda, Marco Petasecca, Anatoly Rosenfeld, and S. Guatelli, Modelling ICRP110 Adult Reference Voxel Phantoms for dosimetric applications: Development of a new Geant4 Advanced Example. (2020).
27- Samira Kamrani, Nima Kasraie, Fatemeh Jahangiri, Davood Khezrloo, and Peyman Sheikhzadeh, "Organ doses, effective dose, and cancer risk estimation from head and neck CT scans." Radiation Physics and Chemistry, Vol. 212p. 111163, 07/01 (2023).
28- C. Anam, F. Haryanto, R. Widita, I. Arif, G. Dougherty, and D. McLean, "Volume computed tomography dose index (CTDIvol) and size-specific dose estimate (SSDE) for tube current modulation (TCM) in CT scanning." Int-J-Radiat-Res, Vol. 16 (No. 3), pp. 289-97, (2018).
29- I. Lange, B. Alikhani, F. Wacker, and H. J. Raatschen, "Intraindividual variation of dose parameters in oncologic CT imaging." (in eng), PLoS One, Vol. 16 (No. 4), p. e0250490, (2021).
30- Rubel Chakravarty, Hao Hong, and Weibo Cai, "Positron Emission Tomography Image-Guided Drug Delivery: Current Status and Future Perspectives." Molecular Pharmaceutics, Vol. 11 (No. 11), pp. 3777-97, 2014/11/03 (2014).
31- Sally Pimlott and Andrew Sutherland, "Molecular tracers for the PET and SPECT imaging of disease." Chemical Society reviews, Vol. 40pp. 149-62, 04/19 (2011).
32- Samira Heidari, Mahdi Sadeghi, Mehdi Akhlaghi, Davood Beiki, and Saeideh Yazdi, "Internal dosimetry of 64Cu-DOX-loaded microcapsules by Monte Carlo method." Applied Radiation and Isotopes, Vol. 196p. 110788, 03/01 (2023).
33- A. W. Wong et al., "A comparison of image contrast with (64)Cu-labeled long circulating liposomes and (18)F-FDG in a murine model of mammary carcinoma." (in eng), Am J Nucl Med Mol Imaging, Vol. 3 (No. 1), pp. 32-43, (2013).
34- P. S. Iyer, "Current radiation protection standards: ICRP-60." Indian Journal of Radiology and Imaging, Vol. 5 (No. 2), pp. 81-83, (1995).
35- Karimipourfard, M., S. Sina, and M. S. Alavi. "Toward three-dimensional patient-specific internal dosimetry using GATE Monte Carlo technique." Radiation Physics and Chemistry 195, 110046, (2022).
36- Jean-Claude Nenot, Jean Brenot, Dominique Laurier, Alain Rannou, and Dominique Thierry, "ICRP Publication 103 The 2007 Recommendations of the International Commission on Radiological Protection." France, 978-2-7430-1120-8, (2009), [Online]. Available: http://inis.iaea.org/search/search.aspx?orig_q=RN:49042116.
37- K. Tamura et al., "64Cu-DOTA-trastuzumab PET imaging in patients with HER2-positive breast cancer." (in eng), J Nucl Med, Vol. 54 (No. 11), pp. 1869-75, Nov (2013).
| Files | ||
| Issue | Articles in Press | |
| Section | Original Article(s) | |
| Keywords | ||
| 64Cu-DOTA-Trastuzumab Internal Dosimetry Positron Emission Tomography Computed Tomography Absorbed Dose | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
How to Cite
1.
Kadhim AA, Sheikhzadeh P, Abbasi M, Afshar S, Vahidfar N, Asidkar S, Karimipourfard M, Valibeiglou Z, Ay MR. Investigating Patient-Specific Absorbed Dose Assessment for Copper-64 PET/CT. Frontiers Biomed Technol. 2024;.
